Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Fig. 4

Whole-exome sequencing of the parental and gene-corrected hiPSCs. No obvious genome change was detected in parental and gene-corrected hiPSCs. Compared with the untargeted β-thal hiPSCs (A), the corrected hiPSCs (B) contain five the same single-nucleotide variations (SNVs), and one disappears indel than that formed from the hiPSCs without corrections

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512